Assessing Edwards Lifesciences: Insights From 14 Financial Analysts
Portfolio Pulse from Benzinga Insights
Edwards Lifesciences (NYSE:EW) has been rated by 14 analysts in the last three months, with a diverse range of opinions. The average 12-month price target is now $76.71, down from the previous $85.58. Recent analyst actions include both upgrades and downgrades, with price targets ranging from $57.00 to $85.00. Edwards Lifesciences, known for its medical devices for structural heart disease, shows strong financial performance with a high net margin and ROE, but its revenue growth lags behind the Health Care sector average.
January 12, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Edwards Lifesciences has received varied analyst ratings with a downward revision in the average price target to $76.71. The company's strong financials may counterbalance the negative sentiment from slower revenue growth.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty, which could lead to a neutral short-term impact on EW's stock price. However, the company's strong financial performance, particularly its high net margin and ROE, may provide a counterbalancing effect, supporting the stock price despite the lowered growth expectations.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100